Clinical trials: Immune System Disease
Atopic Dermatitis
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- UP-TAINED (NCT05139836)
- Where
- 125 sites in Germany
- Volunteers
- 634 people
- Sponsor
- AbbVie
Multiple Myeloma, Neoplasms
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
The purpose of this study is to see how long lenalidomide therapy can maintain or improve the disease response obtained after induction therapy that does not include lenalidomide, pomalidomide or thalidomide; and consequently…
- Conditions
- Multiple Myeloma, Neoplasms, Plasma Cells, Paraproteinemias
- Trial name
- NCT02155634
- Testing
- Lenalidomide
- Sponsor
- Celgene
Plaque Psoriasis
A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
IMO 8400 is a second-generation oligonucleotide antagonist of endosomal Toll-like receptors (TLR) 7, TLR8 and TLR9. These TLR react to complexes of exogenous nucleic acids (as might be encountered during infection) and endogenous…
- Trial name
- 8400-201 (NCT01899729)
- Testing
- IMO-8400 Regimen 1, IMO-8400 Regimen 2, IMO-8400 Regimen 3
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Idera Pharmaceuticals, Inc.
HIV Infections
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day…
- Trial name
- NCT00294372
- Testing
- BILR 355 BS
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis
Efficacy of the "Атопик Soothing Cream" in Children With Mild to Moderate Atopic Dermatitis
A Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy of the "Атопик Soothing Cream" in Children with Mild to Moderate Atopic Dermatitis
- Trial name
- NCT02716181
- Testing
- "Атопик Soothing Cream"
- Where
- Russia
- Volunteers
- 74 people
- Sponsor
- Avanta Trading Ltd.
Autoimmune Diseases
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
This study aims to evaluate the safety, tolerability and PK of repeat dose administration of GSK2618960 in the treatment of pSS.
- Trial name
- NCT03239600
- Testing
- GSK2618960 2 mg/kg, Methotrexate
- Where
- United Kingdom
- Sponsor
- GlaxoSmithKline
HIV Infections
Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)
To evaluate the management of HIV-1 participants treated with antiretroviral combination therapy including the integrase inhibitor raltegravir, all across the country of France.
- Trial name
- RACING (NCT01048671)
- Testing
- Raltegravir, ARV (non-raltegravir)
- Volunteers
- 482 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenosine Deaminase Deficiency
Investigation of ADA Enzyme Deficiency
This observational study was designed as a prospective epidemiological screening study. Patients who applied to the centers participating in the study and were found to be lymphopenic in at least one examination will be included…
- Trial name
- NCT05300334
- Testing
- adenosine deaminase test
- Where
- Turkey (Türkiye)
- Volunteers
- 800 people
- Sponsor
- TRPHARM
Diabetes, Diabetes Mellitus, Type 1
A Trial Assessing Changes in Blood Sugar and the Number of Periods Where Supplementation of Carbohydrate is Needed to Treat Low Blood Sugar, During Two Different Treatment Regimens of NN1250 in Type 1 Diabetics
This trial is conducted in Europe. The aim is to compare changes in blood sugar and the number of periods where carbohydrate supplementation is needed to treat low blood sugar, during two different treatments with NN1250 (insulin…
- Trial name
- NCT00964964
- Testing
- insulin degludec
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
The purpose of this study is to find out if baricitinib can delay the onset of clinical type 1 diabetes (T1D) in people who are at high risk to develop T1D. Participation in the study will last up to approximately 5 years.
- Trial name
- BARICADE-DELAY (NCT07222137)
- Testing
- Baricitinib
- Where
- 112 sites in United States, Australia and 17 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
The purpose of this phase I/Ib study was to determine the safety profile of NIZ985 (new formulation), and if it could be safely combined with spartalizumab or tislelizumab and to determine the appropriate dose and schedule for…
- Trial name
- NCT04261439
- Testing
- NIZ985, Spartalizumab, Tislelizumab
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Traumatic Brain Injury
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure…
- Trial name
- NCT05951777
- Testing
- Autologous HB-adMSCs, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Hope Biosciences LLC
Hepatitis B
Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine
In this study, subjects who received primary neonatal vaccination with hepatitis B vaccine at 0, 1, 2, 12 months, 20 years ago in the 103860/272 primary study will be evaluated for immunological memory to hepatitis B vaccine via…
- Trial name
- NCT00657657
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
B-cell Acute Lymphoblastic Leukemia
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or…
- Trial name
- NCT06450067
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- Juventas Cell Therapy Ltd.
Asthma
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo.
- Trial name
- NCT01340209
- Testing
- Tiotropium Respimat
- Where
- 55 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 1
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
The investigators are doing this study to see the effect of insulin degludec in pregnant women with type 1 diabetes, and if it is safe to use.
- Trial name
- EXPECT (NCT03377699)
- Testing
- Insulin degludec, Insulin Aspart, Insulin detemir
- Where
- 71 sites in Argentina, Australia and 13 more
- Volunteers
- 225 people
- Sponsor
- Novo Nordisk A/S
HIV Infections
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
This single arm study will evaluate the efficacy, safety and tolerability of a new investigational protease inhibitor (PI) plus background antiretrovirals plus Fuzeon (90mg sc bid) in HIV-1 infected, triple-class…
- Trial name
- NCT00326963
- Testing
- Background ARVs, PI, enfuvirtide [Fuzeon]
- Where
- 38 sites in United States, Australia
- Volunteers
- 142 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
- Trial name
- NCT00030966
- Testing
- Natalizumab
- Where
- 88 sites in United States, Austria and 5 more
- Volunteers
- 1,200 people
- Sponsor
- Biogen
Infection, Human Immunodeficiency Virus
A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects
This study will evaluate two new GSK1265744 sodium salt tablet formulations and provide data for selection of one of these tablet formulations for use in Phase 3.
- Trial name
- NCT02059031
- Testing
- GSK1265744 Reference formulation, GSK1265744 New formulation 1, GSK1265744 New formulation 2
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Rheumatoid Arthritis
First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts
This is a randomized, double-blind, placebo-controlled, first-in-human phase I study. It consists of a single ascending dose part in healthy subjects (Part 1) and in patients with rheumatoid arthritis (Part 2) as well as a…
- Trial name
- NCT05576012
- Testing
- SOL-116
- Where
- 2 sites in Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Lipum AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.